TY - JOUR
T1 - Comparative efficacy of tisagenlecleucel and lisocabtagene maraleucel among adults with relapsed/refractory large B-cell lymphomas
T2 - an indirect treatment comparison
AU - Schuster, Stephen J.
AU - Zhang, Jie
AU - Yang, Hongbo
AU - Agarwal, Abhijit
AU - Tang, Wenxi
AU - Martinez-Prieto, Marcela
AU - Bollu, Vamsi
AU - Kuzan, David
AU - Maziarz, Richard T.
AU - Kersten, Marie José
N1 - Publisher Copyright:
© 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2022
Y1 - 2022
N2 - This study compared overall survival (OS), progression-free survival (PFS), complete response rate (CRR), and overall response rate (ORR) of tisagenlecleucel (tisa-cel) and lisocabtagene maraleucel (liso-cel) in relapsed or refractory large B-cell lymphomas (r/r LBCL). Using matching-adjusted indirect comparison (MAIC), individual patient-level data from JULIET (tisa-cel) were weighted to match the patient population in TRANSCEND (liso-cel). The main analysis compared infused JULIET patients (N = 106) with the TRANSCEND efficacy-evaluable set (EES) (N = 256 [infused]). After adjustment, OS, PFS, and the CRR were comparable between tisa-cel and liso-cel EES patients. The estimated adjusted 2-year OS, 2-year PFS, ORR, and CRR were 45.6, 38.2, 62.9, and 47.7%, respectively, for tisa-cel vs. 43.8, 42.1, 72.7, and 53.1% for liso-cel. A scenario analysis compared JULIET patients to the TRANSCEND primary analysis set (PAS) (N = 133). ORR was significantly higher in the TRANSCEND PAS compared with matched JULIET patients, but no significant differences in CRR were observed.
AB - This study compared overall survival (OS), progression-free survival (PFS), complete response rate (CRR), and overall response rate (ORR) of tisagenlecleucel (tisa-cel) and lisocabtagene maraleucel (liso-cel) in relapsed or refractory large B-cell lymphomas (r/r LBCL). Using matching-adjusted indirect comparison (MAIC), individual patient-level data from JULIET (tisa-cel) were weighted to match the patient population in TRANSCEND (liso-cel). The main analysis compared infused JULIET patients (N = 106) with the TRANSCEND efficacy-evaluable set (EES) (N = 256 [infused]). After adjustment, OS, PFS, and the CRR were comparable between tisa-cel and liso-cel EES patients. The estimated adjusted 2-year OS, 2-year PFS, ORR, and CRR were 45.6, 38.2, 62.9, and 47.7%, respectively, for tisa-cel vs. 43.8, 42.1, 72.7, and 53.1% for liso-cel. A scenario analysis compared JULIET patients to the TRANSCEND primary analysis set (PAS) (N = 133). ORR was significantly higher in the TRANSCEND PAS compared with matched JULIET patients, but no significant differences in CRR were observed.
KW - Lisocabtagene maraleucel
KW - matching-adjusted indirect comparison
KW - relapsed or refractory large B-cell lymphoma
KW - tisagenlecleucel
UR - http://www.scopus.com/inward/record.url?scp=85122257799&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85122257799&partnerID=8YFLogxK
U2 - 10.1080/10428194.2021.2010069
DO - 10.1080/10428194.2021.2010069
M3 - Article
C2 - 34978255
AN - SCOPUS:85122257799
SN - 1042-8194
VL - 63
SP - 845
EP - 854
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 4
ER -